Alzheimer Society of Ontario Welcomes U.S. Regulatory Approval of Treatment for Alzheimer's Disease
Timely access to disease-modifying therapies crucial to slowing progression of symptoms TORONTO, Jan. 6, 2023 /CNW/ - The Alzheimer Society of Onta...
Timely access to disease-modifying therapies crucial to slowing progression of symptoms TORONTO, Jan. 6, 2023 /CNW/ - The Alzheimer Society of Ontario is welcoming a U.S. Food and Drug Administration decision released today to grant approval to Leqembi (lecanemab) under its Accelerated Approval pathway. This decision gives hope to the hundreds of thousands of Ontarians who are at heightened risk of developing Alzheimer's disease that an effective pharmacological intervention could be available here in Ontario in years—not decades.